Palvella Therapeutics Q3 net loss widens on higher costs
Overview
US rare skin disease drug developer's Q3 net loss widened yr/yr on higher R&D and admin costs
Company had $236.7 mln in cash, cash equivalents and short-term investments at quarter end
FDA accepted NDA for QTORIN rapamycin, grants priority review with Feb 2027 target action date
Outlook
Company preparing for standalone U.S. commercial launch of QTORIN rapamycin in H1 2027, if approved
Phase 3 trial of QTORIN rapamycin for cutaneous venous malformations expected to begin in Q4 2026
Topline results from Phase 2 LOTU trial in angiokeratomas expected in H2 2027
Result Drivers
R&D SPENDING - Higher research and development expenses driven by increased manufacturing activity, clinical development for angiokeratomas, NDA submission costs, and increased headcount and consulting services
ADMINISTRATIVE COSTS - Higher general and administrative expenses due to increased headcount and professional services related to operating as a public company
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Loss Per Share | $1.70 | ||
Q3 Net Loss | $24.64 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Palvella Therapeutics Inc is $229.00, about 41.1% above its November 4 closing price of $162.28
Reuters Recommended Reads
Nov 2 - FDA to review uniQure's Huntington's gene therapy, decision due on May 2027
Nov 3 - Rhythm Pharma Q3 net loss narrower than estimated on IMCIVREE demand
Nov 4 - Kailera Therapeutics Q3 net loss widens on higher R&D costs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)